Iktos’s AI technology, based on deep generative models, helps bring speed and efficiency to the drug discovery process. Iktos’ technology automatically designs virtual novel molecules that have all of the characteristics of a successful drug molecule.

Iktos AI is the first company to release user-friendly and high-performance de novo design software for multi-parameter optimization that can be used by any medicinal or computational chemist, whatever their level of expertise, in deep learning and computer programming.

BioExcel is partnering with Iktos on the application of advanced molecular modelling and simulation techniques to expedite drug design.